WO2018207923A1 - 間葉系幹細胞の製造方法、およびその応用 - Google Patents
間葉系幹細胞の製造方法、およびその応用 Download PDFInfo
- Publication number
- WO2018207923A1 WO2018207923A1 PCT/JP2018/018391 JP2018018391W WO2018207923A1 WO 2018207923 A1 WO2018207923 A1 WO 2018207923A1 JP 2018018391 W JP2018018391 W JP 2018018391W WO 2018207923 A1 WO2018207923 A1 WO 2018207923A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- acid sequence
- differentiation
- recombinant gelatin
- cells
- Prior art date
Links
- 210000002901 mesenchymal stem cell Anatomy 0.000 title claims abstract description 82
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 23
- 210000004027 cell Anatomy 0.000 claims abstract description 109
- 108010010803 Gelatin Proteins 0.000 claims abstract description 106
- 239000008273 gelatin Substances 0.000 claims abstract description 106
- 229920000159 gelatin Polymers 0.000 claims abstract description 106
- 235000019322 gelatine Nutrition 0.000 claims abstract description 106
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 106
- 230000004069 differentiation Effects 0.000 claims abstract description 103
- 238000000034 method Methods 0.000 claims abstract description 64
- 210000001789 adipocyte Anatomy 0.000 claims abstract description 63
- 229920001436 collagen Polymers 0.000 claims abstract description 32
- 102000008186 Collagen Human genes 0.000 claims abstract description 31
- 108010035532 Collagen Proteins 0.000 claims abstract description 31
- 239000007788 liquid Substances 0.000 claims abstract description 29
- 238000012258 culturing Methods 0.000 claims abstract description 17
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 21
- 150000001413 amino acids Chemical class 0.000 claims description 100
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 claims description 20
- 238000012423 maintenance Methods 0.000 claims description 14
- 210000001185 bone marrow Anatomy 0.000 claims description 12
- 230000021164 cell adhesion Effects 0.000 claims description 10
- 210000000845 cartilage Anatomy 0.000 claims description 8
- 230000001939 inductive effect Effects 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 5
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 claims description 2
- 239000002609 medium Substances 0.000 description 80
- 235000001014 amino acid Nutrition 0.000 description 46
- 229940024606 amino acid Drugs 0.000 description 46
- 230000006698 induction Effects 0.000 description 24
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 238000010899 nucleation Methods 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 210000000130 stem cell Anatomy 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- 230000009815 adipogenic differentiation Effects 0.000 description 5
- 210000001612 chondrocyte Anatomy 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
- 239000004473 Threonine Substances 0.000 description 4
- 235000009582 asparagine Nutrition 0.000 description 4
- 229960001230 asparagine Drugs 0.000 description 4
- 210000004413 cardiac myocyte Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 235000004400 serine Nutrition 0.000 description 4
- 235000008521 threonine Nutrition 0.000 description 4
- 235000002374 tyrosine Nutrition 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 3
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 3
- 235000010724 Wisteria floribunda Nutrition 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- XQQUSYWGKLRJRA-RABCQHRBSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-3-methylbutanoic acid Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O XQQUSYWGKLRJRA-RABCQHRBSA-N 0.000 description 2
- MWOGMBZGFFZBMK-LJZWMIMPSA-N (2s)-2-[[(2s)-2-[[2-[[(2s,3s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical group NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 MWOGMBZGFFZBMK-LJZWMIMPSA-N 0.000 description 2
- 102100032141 Cell death activator CIDE-A Human genes 0.000 description 2
- 101710196996 Cell death activator CIDE-A Proteins 0.000 description 2
- 102000000503 Collagen Type II Human genes 0.000 description 2
- 108010041390 Collagen Type II Proteins 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 101001123331 Homo sapiens Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 101100015391 Mus musculus Ralgds gene Proteins 0.000 description 2
- 102100028960 Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- TZSMWSKOPZEMAJ-UHFFFAOYSA-N bis[(2-methoxyphenyl)methyl] carbonate Chemical compound COC1=CC=CC=C1COC(=O)OCC1=CC=CC=C1OC TZSMWSKOPZEMAJ-UHFFFAOYSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000002449 bone cell Anatomy 0.000 description 2
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 235000004554 glutamine Nutrition 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 125000001841 imino group Chemical group [H]N=* 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- VOFUROIFQGPCGE-UHFFFAOYSA-N nile red Chemical compound C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=O)C2=C1 VOFUROIFQGPCGE-UHFFFAOYSA-N 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 210000004409 osteocyte Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- HZHXMUPSBUKRBW-FXQIFTODSA-N (4s)-4-[[2-[[(2s)-2-amino-3-carboxypropanoyl]amino]acetyl]amino]-5-[[(1s)-1-carboxyethyl]amino]-5-oxopentanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O HZHXMUPSBUKRBW-FXQIFTODSA-N 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229920001342 Bakelite® Polymers 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102100037241 Endoglin Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- QXPRJQPCFXMCIY-NKWVEPMBSA-N Gly-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN QXPRJQPCFXMCIY-NKWVEPMBSA-N 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101000928537 Homo sapiens Delta-like protein 1 Proteins 0.000 description 1
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 1
- 101000942967 Homo sapiens Leukemia inhibitory factor Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 102000018728 Inhibitor of Differentiation Proteins Human genes 0.000 description 1
- 108010052370 Inhibitor of Differentiation Proteins Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100022165 Nuclear factor 1 B-type Human genes 0.000 description 1
- 101710170464 Nuclear factor 1 B-type Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000004637 bakelite Substances 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 210000003074 dental pulp Anatomy 0.000 description 1
- 230000035194 endochondral ossification Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 108010088381 isoleucyl-lysyl-valyl-alanyl-valine Proteins 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000009818 osteogenic differentiation Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108091006084 receptor activators Proteins 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000023895 stem cell maintenance Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 150000004669 very long chain fatty acids Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/54—Collagen; Gelatin
Definitions
- the present invention relates to a method for producing mesenchymal stem cells in which differentiation into adipocytes is suppressed by a simple process.
- the present invention relates to a method for producing differentiation-induced cells, which comprises the step of culturing the mesenchymal stem cells in which differentiation into adipocytes is suppressed in the differentiation-inducing medium.
- the present invention relates to mesenchymal stem cells and differentiation-induced cells produced by the method described above.
- the present invention further relates to an agent for suppressing differentiation into adipocytes.
- adipocytes The basis for the onset of obesity and metabolic syndrome associated with adipocyte accumulation in vivo is the inflammatory response by macrophages present in the accumulated adipocytes.
- the origin of adipocytes is mesenchymal stem cells, from which osteocytes, chondrocytes, cardiomyocytes, adipocytes and the like are derived from mesenchymal stem cells. Methods for suppressing differentiation of mesenchymal stem cells are being investigated.
- Patent Document 1 describes a method of preserving a mesenchymal stem cell population using a gel and a matrix having a rigidity in the range of 150 to 750 kPa.
- Patent Document 2 describes a fat differentiation inhibitor containing, as an active ingredient, a cyclic peptide having a sequence similar to one of the cysteine rich domains of RANK (receptor activator of NF--B).
- Patent Document 3 describes a peptide having a specified amino acid sequence and having an activity of inducing suppression of proliferation and differentiation of human bone marrow stem cells.
- Patent Document 4 describes a poly having a stem cell differentiation inhibitory activity, which is obtained by expressing a polypeptide obtained from the sequence of human Delta1 in a minimal unit in a prokaryotic cell and purifying it using a denaturing agent and a reducing agent. Peptides are described.
- gelatin is known as a representative scaffold material in regenerative medicine.
- Gelatin is known as a highly biocompatible and highly safe material and has a high track record of application in medical applications.
- Patent Document 5 describes a cell support composed of a recombinant gelatin (recombinant gelatin) and composed of a porous body having predetermined properties.
- Patent Document 1 acrylamide and bisacrylamide are mixed at a ratio within a predetermined range, and gelation is performed to prepare a gel having a predetermined rigidity, but the operation is complicated.
- Patent Documents 2 to 4 describe that differentiation to fat is suppressed using a peptide or polypeptide, but a method for suppressing differentiation of mesenchymal stem cells to adipocytes by a simpler process. Is desired.
- the object of the present invention is to provide a method for producing mesenchymal stem cells in which differentiation into adipocytes is suppressed by simple steps, and mesenchymal stem cells produced by the above method.
- Another object of the present invention is to provide a method for producing differentiation-induced cells using the above-described method for producing mesenchymal stem cells, and differentiation-induced cells produced by the above method.
- Yet another object of the present invention is to provide an adipocyte differentiation inhibitor.
- mesenchymal stem cells into adipocytes by culturing mesenchymal stem cells in a liquid medium in which recombinant gelatin having an amino acid sequence derived from a partial amino acid sequence of collagen is dissolved. It has been found that it is possible to produce mesenchymal stem cells in which differentiation of the stem cells is suppressed.
- the present invention has been completed based on these findings.
- a method for producing mesenchymal stem cells in which differentiation into adipocytes is suppressed comprising the step of culturing mesenchymal stem cells in a liquid medium in which a recombinant gelatin having an amino acid sequence derived from a partial amino acid sequence of collagen is dissolved. .
- the recombinant gelatin has a repeat of the sequence represented by Gly-XY characteristic of collagen, X and Y each independently represent any one of amino acids, and a plurality of Gly-XY are The method according to ⁇ 1>, wherein the molecular weight of the recombinant gelatin may be the same or different, and the molecular weight of the recombinant gelatin is 2 kDa or more and 100 kDa or less.
- the recombinant gelatin has a repeat of the sequence represented by Gly-XY which is characteristic of collagen, and X and Y each independently represent any one of amino acids, and a plurality of Gly-XY are The method according to ⁇ 1> or ⁇ 2>, wherein the molecular weight of the recombinant gelatin may be the same or different and is 10 kDa or more and 90 kDa or less.
- the recombinant gelatin has a repeat of the sequence represented by Gly-XY which is characteristic of collagen, and X and Y each independently represent any one of the amino acids, and a plurality of Gly-XY are The method according to any one of ⁇ 1> to ⁇ 3>, wherein the recombinant gelatin may contain the same or different cell adhesion signals in one molecule, which may be the same or different.
- the cell adhesion signal is an amino acid sequence represented by Arg-Gly-Asp.
- ⁇ 6> The method according to any one of ⁇ 1> to ⁇ 5>, wherein the amino acid sequence of the recombinant gelatin is represented by the following formula.
- A-[(Gly-XY) n ] m- B wherein A represents any amino acid or amino acid sequence, B represents any amino acid or amino acid sequence, and each of n Xs independently represents an amino acid
- n Ys independently represent any one of amino acids
- n represents an integer of 3 to 100
- m represents an integer of 2 to 10.
- the n pieces of Gly-X-Y may be the same or different.
- 63 X each independently represent any of amino acids
- 63 Y independently represent any of amino acids Show.
- the 63 Gly-X-Y groups may be the same or different.
- the method according to any one of ⁇ 1> to ⁇ 8>, wherein the mesenchymal stem cells are bone marrow derived cells or cartilage derived cells.
- ⁇ 10> The method according to any one of ⁇ 1> to ⁇ 9>, wherein a liquid medium in which a recombinant gelatin having an amino acid sequence derived from a partial amino acid sequence of collagen is dissolved is a liquid medium for maintenance of undifferentiation.
- a liquid medium in which a recombinant gelatin having an amino acid sequence derived from a partial amino acid sequence of collagen is dissolved is a liquid medium for maintenance of undifferentiation.
- concentration in the liquid medium in which the recombinant gelatin having an amino acid sequence derived from the partial amino acid sequence of collagen is dissolved is 0.01 ⁇ g / mL to 500 ⁇ g / mL The method described in.
- ⁇ 12> Any one of ⁇ 1> to ⁇ 10>, wherein the concentration in the liquid medium in which the recombinant gelatin having an amino acid sequence derived from the partial amino acid sequence of collagen is dissolved is 0.02 ⁇ g / mL to 300 ⁇ g / mL The method described in.
- ⁇ 13> A step of producing mesenchymal stem cells in which differentiation into adipocytes is suppressed by the method according to any one of ⁇ 1> to ⁇ 12>, and differentiation into the above-described adipocytes in a differentiation induction medium
- a method of producing a differentiation-induced cell comprising the step of culturing mesenchymal stem cells in which the ⁇ 14> Mesenchymal stem cells produced by the method according to any one of ⁇ 1> to ⁇ 12>.
- ⁇ 15> A differentiation-induced cell produced by the method according to ⁇ 13>.
- An agent for suppressing differentiation into adipocytes comprising recombinant gelatin having an amino acid sequence derived from a partial amino acid sequence of collagen.
- mesenchymal stem cells in which differentiation into adipocytes is suppressed can be produced by a simple process.
- desired cells can be produced by simple steps.
- the mesenchymal stem cells and differentiation-induced cells produced by the method of the present invention are useful in regenerative medicine and the like.
- mesenchymal stem cells in which differentiation into adipocytes is suppressed can be produced by a simple process.
- FIG. 1 shows the results of staining of cells with oil red to confirm differentiation into adipocytes in the case where the cells are UDE BM and the medium is MesenPro.
- FIG. 2 shows the results of staining of the cells with oil red to confirm differentiation into adipocytes in the case where the cells are UDE BM and the medium is DMEM.
- FIG. 3 shows the results of staining of cells with oil red to confirm differentiation into adipocytes in the case where the cells are UDE BM and the medium is PRIME-XV.
- FIG. 4 shows the results of staining of cells with oil red to confirm differentiation into adipocytes in the case where the cell is Yub 2505 and the medium is PRIME-XV.
- FIG. 1 shows the results of staining of cells with oil red to confirm differentiation into adipocytes in the case where the cells are UDE BM and the medium is MesenPro.
- FIG. 2 shows the results of staining of the cells with oil red to confirm differentiation into adipocyte
- FIG. 5 shows that when the cells are BMSC (Lonza: PT-2501) and the culture medium is MesenPro and cultured with different amounts of recombinant gelatin, Lonza (A in the upper row of FIG. 5) or PromoCell (FIG. 5).
- the results of staining the cells differentiated into fat using the fat differentiation induction medium of the lower part B) with Nile red to confirm differentiation into fat cells are shown.
- FIG. 6 shows the result of counting the number of cells differentiated into fat for the photomicrograph of FIG. A in the upper part of FIG. 6 is a case where fat differentiation is performed using a Lonza fat differentiation induction medium, and B in a lower part of FIG. 6 is a case where fat differentiation is performed using a fat differentiation induction medium of PromoCell.
- FIG. 7 shows the results of measurement of the number of cells by culturing with different amounts of recombinant gelatin and culturing when the cells are BMSC (Lonza: PT-2501) and the medium
- the present invention relates to a method for producing mesenchymal stem cells in which differentiation into adipocytes is suppressed, and in particular, in a liquid medium in which a recombinant gelatin having an amino acid sequence derived from a partial amino acid sequence of collagen is dissolved.
- a method comprising the step of culturing stem cells.
- differentiation of mesenchymal stem cells into adipocytes can be suppressed.
- the therapeutic effect is to avoid tissue differentiation of unintended directions (for example, adipocytes) of mesenchymal stem cells susceptible to surrounding microenvironment in vivo Important in the sense of securing
- the cells obtained by the method of the present invention can be used, for example, for bone tissue repair or cartilage tissue repair in regenerative medicine.
- mesenchymal stem cells are cultured in a liquid medium in which recombinant gelatin having an amino acid sequence derived from a partial amino acid sequence of collagen is dissolved.
- the timing at which mesenchymal stem cells are cultured in a liquid medium in which recombinant gelatin is dissolved is not particularly limited, and may be any one of mesenchymal stem cell maintenance or expansion culture and differentiation induction culture of mesenchymal stem cells. And both of the above.
- mesenchymal stem cells can be cultured in a liquid medium in which recombinant gelatin has been dissolved.
- the liquid medium in which the recombinant gelatin having an amino acid sequence derived from the partial amino acid sequence of collagen is dissolved is a liquid medium for maintenance of undifferentiation.
- the mesenchymal system can be obtained by the simple operation of adding the recombinant gelatin to the medium only during maintenance or expansion culture of the mesenchymal stem cells (the addition of the recombinant gelatin to the differentiation-inducing medium is unnecessary). Differentiation of stem cells into adipocytes can be suppressed.
- recombinant gelatin means a polypeptide or protein-like substance having a gelatin-like amino acid sequence produced by genetic engineering technology.
- the recombinant gelatin which can be used in the present invention is preferably one having a repeat of the sequence represented by Gly-XY characteristic of collagen (X and Y each independently represent any amino acid).
- the plurality of Gly-X-Y may be the same or different.
- two or more sequences of cell adhesion signals are contained in one molecule.
- gelatin having an amino acid sequence derived from a partial amino acid sequence of human collagen can be used.
- the present invention is not limited thereto.
- Preferred as the recombinant gelatin used in the present invention is a gelatin of the following aspect.
- the recombinant gelatin is excellent in biocompatibility due to the natural performance of natural gelatin, and is not of natural origin, so there is no concern such as bovine spongiform encephalopathy (BSE) and is excellent in noninfectiousness. Since recombinant gelatin does not contain animal-derived components, mesenchymal stem cells can be cultured under conditions of serum free (Serum free) and animal derived components (Xeno free). In addition, recombinant gelatin can be designed with precision because it is homogeneous compared to natural gelatin and its sequence has been determined.
- BSE bovine spongiform encephalopathy
- the molecular weight of the recombinant gelatin is not particularly limited, but is preferably 2000 or more and 100000 or less (2 kDa or more and 100 kDa or less), more preferably 2500 or more and 95000 or less (2.5 kDa or more and 95 kDa or less), further preferably 5000 or more and 90,000. It is the following (5 kDa or more and 90 kDa or less), and most preferably 10000 or more and 90000 or less (10 kDa or more and 90 kDa or less).
- the recombinant gelatin preferably has a repeat of the sequence shown by Gly-XY characteristic of collagen.
- the plurality of Gly-X-Y may be the same or different.
- Gly-XY Gly represents glycine
- X and Y each independently represent any amino acid (preferably, any amino acid other than glycine).
- the sequence represented by Gly-XY, which is characteristic of collagen, is a highly specific partial structure in the amino acid composition and sequence of gelatin-collagen as compared with other proteins. In this part, glycine accounts for about one third of the whole, and in the amino acid sequence, one out of every three repeats.
- Glycine is the simplest amino acid, has less restriction on the arrangement of molecular chains, and greatly contributes to regeneration of the helical structure upon gelation.
- the amino acids represented by X and Y contain a large amount of imino acids (proline and oxyproline), and preferably occupy 10% to 45% of the total.
- at least 80%, more preferably at least 95%, most preferably at least 99% of the amino acids of the recombinant gelatin sequence are the repeated structure of Gly-XY.
- common polar amino acids are charged and uncharged at 1: 1.
- polar amino acids specifically refer to cysteine, aspartic acid, glutamic acid, histidine, lysine, asparagine, glutamine, serine, threonine, tyrosine and arginine
- polar uncharged amino acids among these include cysteine, asparagine, glutamine, serine , Threonine and tyrosine.
- the proportion of polar amino acids is 10 to 40%, preferably 20 to 30%, of the total amino acids constituting the composition.
- the proportion of uncharged amino acids in the polar amino acids is preferably 5% or more and less than 20%, preferably less than 10%. Furthermore, it is preferable not to include any one amino acid of serine, threonine, asparagine, tyrosine and cysteine, preferably two or more amino acids in the sequence.
- polypeptides the minimum amino acid sequence that works as a cell adhesion signal is known (eg, “Pathophysiology” Vol. 9, No. 7 (1990) page 527) published by Nagai Publishing Co., Ltd.
- the recombinant gelatin used in the present invention preferably has two or more of these cell adhesion signals in one molecule.
- Specific sequences include RGD sequence, LDV sequence, REDV sequence, YIGSR sequence, PDSGR sequence, RYVVLPR sequence, LGTIPG sequence, RNIAEIIKDI sequence, which are represented by single-letter amino acid notation in that there are many types of cells to adhere to.
- Preferred are the sequences of IKVAV, LRE, DGEA and HAV sequences. More preferred are RGD sequences, YIGSR sequences, PDSGR sequences, LGTIPG sequences, IKVAV sequences and HAV sequences, and particularly preferred are RGD sequences.
- glycosaminoglycan (GAG)
- the number of amino acids between RGDs is not uniform between 0 and 100, preferably between 25 and 60.
- the content of the minimum amino acid sequence is preferably 3 to 50, more preferably 4 to 30, and particularly preferably 5 to 20 in one molecule of protein from the viewpoint of cell adhesion and proliferation. Most preferably, it is twelve.
- the ratio of the RGD motif to the total number of amino acids is preferably at least 0.4%. Where the gelatin comprises more than 350 amino acids, it is preferred that each stretch of 350 amino acids comprises at least one RGD motif.
- the ratio of the RGD motif to the total number of amino acids is more preferably at least 0.6%, more preferably at least 0.8%, still more preferably at least 1.0%, further preferably at least 1.2%. Most preferably at least 1.5%.
- the number of RGD motifs in the peptide is preferably at least 4, more preferably at least 6, more preferably at least 8, more preferably 12 or more and 16 or less per 250 amino acids.
- a percentage of 0.4% of the RGD motif corresponds to at least one RGD sequence per 250 amino acids.
- gelatin consisting of 251 amino acids must contain at least two RGD sequences in order to meet the feature of at least 0.4%.
- the gelatin in the present invention comprises at least 2 RGD sequences per 250 amino acids, more preferably at least 3 RGD sequences per 250 amino acids, more preferably at least 4 RGDs per 250 amino acids. Contains an array.
- a further embodiment of gelatin in the present invention comprises at least 4 RGD motifs, preferably at least 6, more preferably at least 8, more preferably 12 to 16 RGD motifs.
- the recombinant gelatin may be partially hydrolyzed.
- the amino acid sequence of the recombinant gelatin used in the present invention is that represented by the formula: A-[(Gly-X-Y) n ] m -B.
- the n X's each independently represent any of the amino acids
- the n Y's each independently represent any of the amino acids.
- m preferably represents an integer of 2 to 10, more preferably an integer of 3 to 5.
- n is preferably an integer of 3 to 100, more preferably an integer of 15 to 70, and most preferably an integer of 50 to 65.
- A represents any amino acid or amino acid sequence
- B represents any amino acid or amino acid sequence.
- the n pieces of Gly-X-Y may be the same or different.
- the amino acid sequence of the recombinant gelatin used in the present invention is of the formula: Gly-Ala-Pro-[(Gly-XY) 63 ] 3 -Gly, wherein each of the 63 X's is independently an amino acid In each case, each of the 63 Ys independently represents any one of the amino acids, and the 63 Gly-X-Ys may be the same or different.
- the naturally occurring collagen referred to here may be any naturally occurring collagen, but is preferably type I, II, III, IV or V collagen. More preferably, it is type I, type II or type III collagen. According to another form, the collagen is preferably human, bovine, porcine, murine or rat, more preferably human.
- the isoelectric point of the recombinant gelatin used in the present invention is preferably 5 to 10, more preferably 6 to 10, and still more preferably 7 to 9.5.
- the measurement of the isoelectric point of the recombinant gelatin is not limited as long as it is a known method that can measure the isoelectric point.
- the isoelectric focusing method Maxey, CR (1976; Phitogr. Gelatin 2, Editor) It can be carried out according to Cox, P. J. Academic, London, Engl.) By measuring the pH after passing a 1% by mass gelatin solution through a mixed crystal column of a cation and anion exchange resin.
- the recombinant gelatin is not deaminated.
- the recombinant gelatin does not have telopentide.
- the recombinant gelatin is a substantially pure polypeptide prepared by a nucleic acid encoding an amino acid sequence.
- the recombinant gelatin used in the present invention is particularly preferably (1) the amino acid sequence of SEQ ID NO: 1 or (2) the amino acid sequence of SEQ ID NO: 1 80% or more (more preferably 90% or more, particularly preferably 95% or more, most preferably 98% or more) And have amino acid sequences with cell adhesion.
- the hydrophilicity value "1 / IOB" value of the recombinant gelatin used in the present invention is preferably 0 to 1.0. More preferably, it is 0 to 0.6, and more preferably 0 to 0.4.
- the IOB is an indicator of hydrophilicity / hydrophobicity based on an organic conceptual diagram representing the polarity / non-polarity of the organic compound proposed by Atsushi Fujita, and the details are described in, for example, "Pharmaceutical Bulletin", vol. 2, 2, pp .163-173 (1954), "Domain of Chemistry” vol. 11, 10, pp. 719-725 (1957), “Fragrance Journal", vol. 50, pp. 79-82 (1981), etc. There is.
- the source of all organic compounds is methane (CH 4 ), and all the other compounds are regarded as derivatives of methane, and their carbon numbers, substituents, modified parts, rings, etc. are set to certain numerical values.
- the scores are added to obtain the organic value (OV) and the inorganic value (IV), and this value is plotted on the diagram with the organic value on the X axis and the inorganic value on the Y axis. It is something.
- the IOB in the organic conceptual diagram means the ratio of the inorganic value (IV) to the organic value (OV) in the organic conceptual diagram, that is, "inorganic value (IV) / organic value (OV)".
- hydrophilicity is expressed by "1 / IOB” value which is the reciprocal of IOB. The smaller the “1 / IOB” value (closer to 0), the more hydrophilic the expression.
- the hydrophilicity index represented by the Grand average of hydropathicity (GRAVY) value is preferably 0.3 or less, -9.0 or more, 0.0 or less, -7.0. It is more preferable that it is more than.
- Grand average of hydropathicity (GRAVY) values can be obtained from Gasteiger E., Hoogland C., Gattiker A., Duvaud S., Wilkins MR, Appel RD, Bairoch A .; Protein Identification and Analysis Tools on the ExPASy Server (In) John M. Walker (ed): The Proteomics Protocols Handbook, Humana Press (2005). Pp.
- the recombinant gelatin used in the present invention can be produced by gene recombination technology known to those skilled in the art, and, for example, to EP 1014176 A2, US Pat. No. 6,992,172, WO 2004/85473, WO 2008/103041 etc. It can manufacture according to the method of a statement. Specifically, a gene encoding an amino acid sequence of a predetermined recombinant gelatin is obtained and incorporated into an expression vector to prepare a recombinant expression vector, which is introduced into an appropriate host to prepare a transformant. . By culturing the obtained transformant in an appropriate medium, recombinant gelatin is produced. Therefore, the recombinant gelatin used in the present invention can be obtained by recovering the recombinant gelatin produced from the culture.
- recombinant gelatin is added to the liquid medium at the time of mesenchymal cell culture.
- the content of recombinant gelatin in the liquid medium in which the recombinant gelatin is dissolved is not particularly limited as long as the effects of the present invention can be achieved, but it is generally 0.1 ng / mL to 500 ⁇ g / mL, preferably 1 ng / mL to 300 ⁇ g / ML.
- the content of recombinant gelatin in the liquid medium in the present invention is much lower (about 1 / 100,000-fold amount) compared to the content of the peptide described in the prior art. Excellent effects (suppression of differentiation to adipocytes) can be achieved even with smaller amounts.
- the recombinant gelatin concentration in the liquid medium in which the recombinant gelatin is dissolved is not particularly limited, but is preferably 0.01 ⁇ g / mL or more, more preferably 0.02 ⁇ m / mL or more, from the viewpoint of the ability to suppress differentiation into adipocytes. 01 ⁇ g / mL or more is more preferable, and 1 ⁇ g / mL or more is most preferable.
- the recombinant gelatin concentration is preferably less than 500 ⁇ g / mL, more preferably less than 300 ⁇ g / mL, still more preferably less than 50 ⁇ g / mL, and most preferably less than 10 ⁇ g / mL from the viewpoint of cell growth rate.
- the concentration of recombinant gelatin in the liquid medium in which the recombinant gelatin is dissolved is preferably 0.01 ⁇ g / mL to less than 500 ⁇ g / mL, more preferably 0.02 ⁇ g / mL to less than 300 ⁇ g / mL, and still more preferably 1 ⁇ g / mL to less than 50 ⁇ g / mL. , 1 ⁇ g / more than 10 ⁇ L is most preferable.
- the type of liquid medium is not particularly limited as long as it is a medium capable of performing maintenance culture or expansion culture of mesenchymal stem cells, for example, MesenPro (2% serum-containing, Life Technologies), Dulbecco's modified Eagle's medium (DMEM) / F12 (containing 20% FBS (fetal bovine serum) (Gibco), Life Technologies), DMEM (containing 10% FBS (Gibco), SIGMA), PRIME-XV XSFM (serum free, JX energy), MSCGM BulletKitTM (Takara Bio), Mesencult-ACF (containing no animal-derived component) and Mesencult-SF (serum-free, all veritas), MSCGM BullrtKit (serum-containing, Lonza) and the like can be mentioned.
- MesenPro 2% serum-containing, Life Technologies
- DMEM Dulbecco's modified Eagle's medium
- F12 containing 20% FBS (fetal bovine serum) (Gibco),
- the mesenchymal stem cells (MSCs) used in the present invention are cells which have the ability to replicate as undifferentiated cells and have the ability to differentiate into osteocytes, chondrocytes, cardiomyocytes, adipocytes and the like.
- the source of mesenchymal stem cells is not particularly limited, and may be human mesenchymal stem cells, or mesenchymal stem cells derived from non-human animals such as mice, rats, cats, or dogs.
- Mesenchymal stem cells are known to be obtainable from various tissues such as bone marrow, cartilage, adipose tissue, placental tissue, umbilical cord tissue, dental pulp, etc.
- the origin is not particularly limited, but mesenchymal stem cells are preferably It is a bone marrow derived cell, a cartilage derived cell or a fat derived cell.
- the mesenchymal stem cells may be autologous cells of the patient to be administered or allogeneic cells.
- mesenchymal stem cells can be suitably separated from the tissue by collagenase method.
- mesenchymal stem cells can be recovered using cell surface markers (CD105, CD73, CD90, etc.) as an indicator.
- ⁇ Culture> As culture conditions for culturing mesenchymal stem cells in a liquid medium in which recombinant gelatin is dissolved, general cell culture conditions may be selected. The conditions of 37 ° C., 5% CO 2 and the like are exemplified. It is preferable to change the medium at an appropriate interval (preferably once every 1 to 7 days, more preferably once every 3 to 4 days) during culture.
- the culture period is not particularly limited, and can be cultured for 1 to 20 days, preferably 3 to 15 days, more preferably 3 to 10 days.
- cell culture vessels such as plates, dishes, flasks for cell culture, bags for cell culture and the like can be used.
- a bag for cell culture what has gas permeability is suitable. If large numbers of cells are required, a large culture vessel may be used. Culturing can be carried out either in an open or closed system.
- the mesenchymal stem cells suppressed in differentiation into adipocytes produced by the method of the present invention have a differentiation ability to adipocytes in comparison with mesenchymal stem cells cultured in a liquid medium not containing recombinant gelatin. It means the mesenchymal stem cells being suppressed.
- the ability to differentiate into adipocytes can be evaluated by confirming differentiation into adipocytes after induction of differentiation into adipocytes by culturing mesenchymal stem cells in an adipocyte differentiation medium.
- Adipocytes can be detected, for example, using morphological changes of cells, characteristic properties of adipocytes, or specific markers. Adipocytes accumulate fat in cells. Therefore, fat cells can be detected by staining of intracellular fat using Oil Red O.
- UCP1 is a type of uncoupling protein. Although quarantine methods (detection by antibodies) can be used for detection of specific markers, detection may be carried out by quantifying the amount of mRNA for protein molecules.
- mesenchymal stem cells produced by the production method of the present invention are provided.
- the mesenchymal stem cells produced by the method of the present invention can be used for cell transplantation.
- the cells of the present invention can be used for the purpose of cell transplantation at a disease site.
- an incision or an endoscope can be used as a transplantation method.
- a method of producing a cell is provided, which comprises the step of culturing a stem cell lineage.
- desired cells can be produced as long as the cells can be induced to differentiate from mesenchymal stem cells. Examples of cells that can be induced to differentiate from mesenchymal stem cells include bone cells, chondrocytes, cardiomyocytes and adipocytes, but are not particularly limited.
- the differentiation induction medium can be appropriately selected according to the type of desired cells to be induced for differentiation.
- Lonza Human Mesenchymal Stem Cell Osteogenic Differentiation Medium Bullet Kit etc.
- Lonza Human Mesenchymal Stem Cell Chlorogenic Differentiation Medium Bullet Kit etc.
- induction of differentiation into cardiomyocytes for example, the method described in JP-A-2009-136209 can be used.
- differentiation induction into adipocytes Lonza: Human Mesenchymal Stem Cell Adipogenic Differentiation Medium Bullet Kit, PromoCell: Mesenchymal Stem Cell Adipogenic Differentiation Medium, etc. can be used.
- the culture conditions for inducing differentiation are the same as the culture conditions when mesenchymal stem cells are cultured in a liquid medium in which recombinant gelatin has been dissolved.
- the culture period for induction of differentiation is also not particularly limited, but generally 3 days to 21 days, preferably 7 days to 18 days.
- differentiation-induced cells produced by the above-described method for producing cells.
- the cells of the invention described above can be used for cell transplantation.
- the differentiation-induced cells of the present invention can be used for the purpose of cell transplantation at a disease site.
- an incision or an endoscope can be used as a transplantation method.
- an agent for suppressing differentiation into adipocytes which comprises a recombinant gelatin having an amino acid sequence derived from a partial amino acid sequence of collagen.
- the details of the recombinant gelatin are as described herein.
- Recombinant gelatin can be used as an adipocyte differentiation inhibitor by dissolving it in a liquid medium for culturing mesenchymal stem cells as described herein.
- the form in the case of providing the recombinant gelatin as an adipocyte differentiation inhibitor is not particularly limited, and the recombinant gelatin may be provided as a solution or a powder, or the recombinant gelatin may be provided in a state of being dissolved in a liquid medium. It is also good.
- CBE3 Recombinant Gelatin
- CBE3 Molecular weight: 51.6 kD structure: Gly-Ala-Pro [(Gly-X-Y) 63 ] 3 -Gly amino acid number: 571
- the amino acid sequence of CBE3 does not include serine, threonine, asparagine, tyrosine and cysteine.
- CBE3 has the ERGD sequence. Isoelectric point: 9.34 GRAVY value: -0.682 1 / IOB value: 0.
- GAP GAPGLQGAPGLQGMPGERGAAGLPGPKGERGDAGPKGADGAPGAPGLQGMPGERGAAGLPGPKGERGDAGPKGADGAPGKDGVRGLAGPIGPPGERGAAGLPGPKGERGDAGPKGADGAPGKDGVRGLAGPIGPPGPAGAPGAPGLQGMPGERGAAGLPGPKGERGDAGPKGADGAPGKDGVRGLAGPIGPPGPAGAPGAPGLQGMPGERGAAGLPGPKGERGDAGPKGADGAPGKDGVRGLAGPP) 3 GAP (GAPGLQGAPGLQGMPGERGAAGLPGPKGERGDAGPKGADGAPGAPGLQGMPGERGAAGLPGPKGERGDAGPKGADGAPGKDGVRGLAGPIGPPGPAGAPGAPGLQGMPGERGAAGLPGPKGERGDAGPKGADGAPGKDGVRGLAGPP) 3 GAP (GAPGLQGAPGLQGMPGERGAAGLPGPKGERGDAGPKGADGAPGKDGVRGLAGPIGPPG
- Example 1 Fat differentiation induction experiment using cartilage-derived cells Yub2505 and bone marrow-derived cells UDE BM (1) Experiment 1: Addition of CBE3 (addition amount: 28 ng / mL) Experiment 2: CBE3 not added
- Yub 2505 (cartilage-derived cells established at the National Research Center for Growth and Medical Research (hereinafter referred to as Seikenken) Yub 2505 is described in the reference (Nasu M, Takayama S, Umezawa A. Endochondral ossification model system: designed cell fate of human epiphyseal chondrocytes during long-term implantation. J. Cell Physiol. 2015; 230: 1376-1388). It was established accordingly.
- UDE BM bone marrow-derived cells established at IRI
- UDE BM was established by the following method. Bone marrow fluid was removed from the bones and cells were collected by density gradient centrifugation. The recovered cells were washed with phosphate buffered saline (PBS), seeded in DMEM (containing 10% FBS) medium and cultured. The cells adhered to the culture vessel were collected.
- PBS phosphate buffered saline
- DMEM containing 10% FBS
- the medium was replaced with MesenPro (8 mL). At that time, CBE3 was added to 28 ng / mL. PBS (Nacalai Tesque) was added to Control instead of CBE3. The culture period was 7 days.
- the medium was changed to a fat differentiation induction medium (2 mL) to start differentiation induction. At that time, differentiation was induced every three or four days, and the medium and the maintenance medium were alternately exchanged. The differentiation induction period was 2 weeks.
- the medium was changed to a maintenance medium (2 mL) and maintenance culture was performed.
- the maintenance culture period was 7 days.
- the cells were stained with oil red, and 25 screens were photographed with a microscope to confirm differentiation into adipocytes.
- Example 2 Fat differentiation induction experiment using human bone marrow-derived cells BMSC (1) Experiment: CBE3 addition (addition amount: 0, 0.028, 2.8, 28, 280 ⁇ g / mL)
- Fat differentiation induction medium Human Mesenchymal Stem Cell Adipogenic Differentiation Medium Bullet Kit (Lonza), PromoCell: Mesenchymal Stem Cell Adipogenic Differentiation Medium
- BMSC cells were maintained and cultured by dispensing 8 mL of MesenPro medium into a culture dish of 10 cm in diameter.
- the cell seeding amount was 5 ⁇ 10 5 cells / well, and the culture period was 6 days.
- the medium was changed to 2 mL of fat differentiation induction medium (Lonza / PromoCell) to start differentiation induction.
- Lonza's medium differentiation was induced every 3 to 4 days, and medium and maintenance medium were alternately exchanged.
- the differentiation induction medium was replaced every three or four days. The differentiation induction period was 17 days.
- the medium was changed to a maintenance medium (2 mL) and maintenance culture was performed.
- the maintenance culture period was 1 day.
- the cells were stained with nile red and 25 screens were photographed with a microscope (Keyence BZ-X700) to confirm differentiation into adipocytes.
- the detection objects of 300 ⁇ m 2 or less were not counted as fat cells, and those exceeding 300 ⁇ m 2 were counted.
- Example 3 Cell proliferation experiment using human bone marrow-derived cells BMSC (1) Experiment: CBE3 addition (addition amount: 0, 0.028, 2.8, 28 ⁇ g / mL)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
<1> コラーゲンの部分アミノ酸配列に由来するアミノ酸配列を有するリコンビナントゼラチンが溶解した液体培地において間葉系幹細胞を培養する工程を含む、脂肪細胞への分化が抑制された間葉系幹細胞の製造方法。
<2> リコンビナントゼラチンが、コラーゲンに特徴的なGly-X-Yで示される配列の繰り返しを有し、XおよびYはそれぞれ独立にアミノ酸の何れかを示し、複数個のGly-X-Yはそれぞれ同一でも異なっていてもよく、リコンビナントゼラチンの分子量が2kDa以上100kDa以下である、<1>に記載の方法。
<3> リコンビナントゼラチンが、コラーゲンに特徴的なGly-X-Yで示される配列の繰り返しを有し、XおよびYはそれぞれ独立にアミノ酸の何れかを示し、複数個のGly-X-Yはそれぞれ同一でも異なっていてもよく、リコンビナントゼラチンの分子量が10kDa以上90kDa以下である、<1>または<2>に記載の方法。
<4> リコンビナントゼラチンが、コラーゲンに特徴的なGly-X-Yで示される配列の繰り返しを有し、XおよびYはそれぞれ独立にアミノ酸の何れかを示し、複数個のGly-X-Yはそれぞれ同一でも異なっていてもよく、リコンビナントゼラチンが細胞接着シグナルを一分子中に2配列以上含む、<1>から<3>の何れか一に記載の方法。
<5> 細胞接着シグナルがArg-Gly-Aspで示されるアミノ酸配列である、<4>に記載の方法。
<6> リコンビナントゼラチンのアミノ酸配列が、下記式で示される、<1>から<5>の何れか一に記載の方法。
A-[(Gly-X-Y)n]m-B式中、Aは任意のアミノ酸またはアミノ酸配列を示し、Bは任意のアミノ酸またはアミノ酸配列を示し、n個のXはそれぞれ独立にアミノ酸の何れかを示し、n個のYはそれぞれ独立にアミノ酸の何れかを示し、nは3~100の整数を示し、mは2~10の整数を示す。なお、n個のGly-X-Yはそれぞれ同一でも異なっていてもよい。
<7> リコンビナントゼラチンのアミノ酸配列が、下記式で示される、<1>から<6>の何れか一に記載の方法。
Gly-Ala-Pro-[(Gly-X-Y)63]3-Gly式中、63個のXはそれぞれ独立にアミノ酸の何れかを示し、63個のYはそれぞれ独立にアミノ酸の何れかを示す。なお、63個のGly-X-Yはそれぞれ同一でも異なっていてもよい。
<8> リコンビナントゼラチンが、(1)配列番号1に記載のアミノ酸配列、または(2)配列番号1に記載のアミノ酸配列と80%以上の配列同一性を有し、細胞接着性を有するアミノ酸配列を有する、<1>から<7>の何れか一に記載の方法。
<9> 間葉系幹細胞が、骨髄由来細胞または軟骨由来細胞である、<1>から<8>の何れか一に記載の方法。
<10> コラーゲンの部分アミノ酸配列に由来するアミノ酸配列を有するリコンビナントゼラチンが溶解した液体培地が、未分化維持用の液体培地である、<1>から<9>の何れか一に記載の方法。
<11> コラーゲンの部分アミノ酸配列に由来するアミノ酸配列を有するリコンビナントゼラチンが溶解した液体培地中の濃度が、0.01μg/mL~500μg/mLである、<1>から<10>の何れか一に記載の方法。
<12> コラーゲンの部分アミノ酸配列に由来するアミノ酸配列を有するリコンビナントゼラチンが溶解した液体培地中の濃度が、0.02μg/mL~300μg/mLである、<1>から<10>の何れか一に記載の方法。
<14> <1>から<12>の何れか一に記載の方法により製造される間葉系幹細胞。
<15> <13>に記載の方法により製造される分化誘導された細胞。
<16> コラーゲンの部分アミノ酸配列に由来するアミノ酸配列を有するリコンビナントゼラチンを含む、脂肪細胞への分化抑制剤。
本発明は、脂肪細胞への分化が抑制された間葉系幹細胞の製造方法に関するものであり、特に、コラーゲンの部分アミノ酸配列に由来するアミノ酸配列を有するリコンビナントゼラチンが溶解した液体培地において間葉系幹細胞を培養する工程を含む方法である。
間葉系幹細胞を用いた細胞治療を行う場合、生体内において周囲の微小環境に影響を受けやすい間葉系幹細胞の意図しない方向(例えば、脂肪細胞)への組織分化を避けることが、治療効果を担保する意味で重要である。本発明の方法により得られる細胞は、例えば再生医療における骨組織修復または軟骨組織修復などに利用することができる。
本発明で言うリコンビナントゼラチンとは、遺伝子組み換え技術により作られたゼラチン類似のアミノ酸配列を有するポリペプチドもしくは蛋白様物質を意味する。本発明で用いることができるリコンビナントゼラチンは、コラーゲンに特徴的なGly-X-Yで示される配列(XおよびYはそれぞれ独立にアミノ酸の何れかを示す)の繰り返しを有するものが好ましい。ここで、複数個のGly-X-Yはそれぞれ同一でも異なっていてもよい。好ましくは、細胞接着シグナルが一分子中に2配列以上含まれている。リコンビナントゼラチンとしては、ヒトコラーゲンの部分アミノ酸配列に由来するアミノ酸配列を有するゼラチンを用いることができる。例えばEP1014176、US特許6992172号、国際公開WO2004/85473、国際公開WO2008/103041等に記載のものを用いることができるが、これらに限定されるものではない。本発明で用いるリコンビナントゼラチンとして好ましいものは、以下の態様のゼラチンである。
この最小アミノ酸配列の含有量は、細胞接着・増殖性の観点から、タンパク質1分子中3~50個が好ましく、さらに好ましくは4~30個、特に好ましくは5~20個である。最も好ましくは12個である。
好ましくは、リコンビナントゼラチンはテロペプタイドを有さない。
好ましくは、リコンビナントゼラチンは、アミノ酸配列をコードする核酸により調製された実質的に純粋なポリペプチドである。
(1)配列番号1に記載のアミノ酸配列、または
(2)配列番号1に記載のアミノ酸配列と80%以上(さらに好ましくは90%以上、特に好ましくは95%以上、最も好ましくは98%以上)の配列同一性を有し、細胞接着性を有するアミノ酸配列を有する。
リコンビナントゼラチンが溶解した液体培地におけるリコンビナントゼラチン濃度は、0.01μg/mL以上500μg/mL未満が好ましく、0.02μg/mL以上300μg/mL未満が好ましく、1μg/mL以上50μg/mL未満が更に好ましく、1μg/以上10μL未満が最も好ましい。
液体培地の種類は、間葉系幹細胞を維持培養または拡大培養できる培地であれば、その種類は特に限定されないが、例えば、MesenPro(2%血清含有、ライフテクノロジーズ)、ダルベッコ改変イーグル培地(DMEM)/F12(20%FBS(ウシ胎児血清)(Gibco)含有、ライフテクノロジーズ)、DMEM(10%FBS(Gibco)含有、SIGMA)、PRIME-XV XSFM(無血清、JXエネルギー)、MSCGM BulletKit(商標)(タカラバイオ)、Mesencult-ACF(動物由来成分不含)及びMesencult-SF(無血清、何れもベリタス)、MSCGM BullrtKit(血清含有、Lonza)などを挙げることができる。
本発明で使用する間葉系幹細胞(MSC)は、未分化細胞としての複製能力を有し、かつ骨細胞、軟骨細胞、心筋細胞および脂肪細胞などへの分化能を有する細胞である。
間葉系幹細胞の起源は特に限定されず、ヒト間葉系幹細胞でもよいし、マウス、ラット、ネコ、またはイヌ等の非ヒト動物由来の間葉系幹細胞でもよい。
間葉系幹細胞は、投与する患者の自家細胞でもよいし、他家細胞でもよい。
リコンビナントゼラチンが溶解した液体培地において間葉系幹細胞を培養する際の培養条件としては、一般的な細胞培養の条件を選択すればよい。37℃、5%CO2の条件などが例示される。培養中は適切な間隔(好ましくは1日から7日に1回、より好ましくは3日から4日に1回)で培地を交換することが好ましい。培養期間は特に限定されず1日~20日間、好ましくは3日~15日間、より好ましくは3日~10日間培養することができる。
本発明の方法により製造される脂肪細胞への分化が抑制された間葉系幹細胞とは、リコンビナントゼラチンを含有しない液体培地において培養した間葉系幹細胞と比較して、脂肪細胞への分化能が抑制されている間葉系幹細胞のことを意味する。
本発明によれば、上記した本発明の方法により脂肪細胞への分化が抑制された間葉系幹細胞を製造する工程、および分化誘導培地において、上記の脂肪細胞への分化が抑制された間葉系幹細胞を培養する工程を含む、細胞の製造方法が提供される。上記の方法によれば、間葉系幹細胞から分化誘導することができる細胞である限り、所望の細胞を製造することができる。間葉系幹細胞から分化誘導することができる細胞としては、骨細胞、軟骨細胞、心筋細胞および脂肪細胞などを挙げることができるが特に限定されない。
骨細胞への分化誘導を行う場合には、Lonza:Human Mesenchymal Stem Cell Osteogenic Differentiation Medium BulletKit等を使用することができる。
軟骨細胞への分化誘導を行う場合には、Lonza:Human Mesenchymal Stem Cell Chondrogenic Differentiation Medium BulletKit等を使用することができる。
脂肪細胞への分化誘導を行う場合には、Lonza:Human Mesenchymal Stem Cell Adipogenic Differentiation Medium BulletKit、PromoCell:Mesenchymal Stem Cell Adipogenic Differentiation Medium等を使用することができる。
本発明によれば、コラーゲンの部分アミノ酸配列に由来するアミノ酸配列を有するリコンビナントゼラチンを含む、脂肪細胞への分化抑制剤が提供される。リコンビナントゼラチンの詳細は本明細書中に記載した通りである。リコンビナントゼラチンは、本明細書中に記載した通り、間葉系幹細胞の培養のための液体培地に溶解することによって、脂肪細胞への分化抑制剤として使用することができる。リコンビナントゼラチンを脂肪細胞への分化抑制剤として提供する場合の形態は特に限定されず、リコンビナントゼラチンを溶液または粉末として提供してもよいし、リコンビナントゼラチンを液体培地に溶解させた状態で提供してもよい。
リコンビナントゼラチンとして以下のCBE3を用意した(国際公開WO2008/103041号公報に記載)。
CBE3:分子量:51.6kD構造: Gly-Ala-Pro[(Gly-X-Y)63]3-Glyアミノ酸数:571個
RGD配列:12個イミノ酸含量:33%ほぼ100%のアミノ酸がGly-X-Yの繰り返し構造である。
CBE3のアミノ酸配列には、セリン、スレオニン、アスパラギン、チロシンおよびシステインは含まれていない。
CBE3はERGD配列を有している。
等電点:9.34
GRAVY値:-0.682
1/IOB値:0.323アミノ酸配列(配列表の配列番号1)(国際公開WO2008/103041号公報の配列番号3と同じ。但し末尾のXは「P」に修正)
GAP(GAPGLQGAPGLQGMPGERGAAGLPGPKGERGDAGPKGADGAPGAPGLQGMPGERGAAGLPGPKGERGDAGPKGADGAPGKDGVRGLAGPIGPPGERGAAGLPGPKGERGDAGPKGADGAPGKDGVRGLAGPIGPPGPAGAPGAPGLQGMPGERGAAGLPGPKGERGDAGPKGADGAPGKDGVRGLAGPP)3G
(1)実験1:CBE3添加(添加量:28ng/mL)
実験2:CBE3無添加
使用細胞:
Yub2505(国立成育医療研究センター(以降、成育研)で樹立された軟骨由来細胞)
Yub2505は参考文献(Nasu M, Takayama S, Umezawa A. Endochondral ossification model system: designed cell fate of human epiphyseal chondrocytes during long-term implantation.J.Cell Physiol.2015;230:1376-1388)に記載の方法に準じて樹立した。
UDE BMは以下の方法で樹立した。骨から骨髄液を取り出し、密度勾配遠心分離によって細胞を集めた。回収した細胞をリン酸緩衝生理食塩水(PBS)で洗浄し、DMEM(10%FBS含有)培地中に播種して培養した。培養容器に接着した細胞を回収した。
MesenPro(2%血清含有、ライフテクノロジーズ):Yub2505、UDE BM
DMEM/F12(20%FBS(Gibco)含有、ライフテクノロジーズ):Yub2505
DMEM(10%FBS(Gibco)含有、SIGMA):UDE BM
PRIME-XV XSFM(無血清、JXエネルギー):Yub2505、UDE BM
脂肪分化誘導培地:Human Mesenchymal Stem Cell Adipogenic Differentiation Medium BulletKit(Lonza)
以下の細胞の培養は全て、37℃5%CO2にて行った。
直径10cmの培養皿にMesenPro培地8mLを分注して各細胞を維持培養した。細胞播種量は1×106cell/培養皿とし、培養期間は5~7日間とした。
脂肪への分化を確認した結果を図1~図4に示す。
細胞がUDE BMであり、培地がMesenProである場合(図1)、細胞がUDE BMであり、培地がDMEMである場合(図2)、細胞がUDE BMであり、培地がPRIME-XVである場合(図3)、細胞がYub2505であり、培地がPRIME-XVである場合(図4)の何れの組み合わせにおいても、実験2(CBE3無添加)に比べて実験1(CBE3添加)は脂肪への分化が抑制されていた。
(1)実験:CBE3添加(添加量:0、0.028、2.8、28、280μg/mL)
使用細胞:
ヒト骨髄由来細胞BMSC(Lonza:PT-2501)
MesenPro(2%血清含有、ライフテクノロジーズ)
脂肪分化誘導培地:Human Mesenchymal Stem Cell Adipogenic Differentiation Medium BulletKit(Lonza)、PromoCell:Mesenchymal Stem Cell Adipogenic Differentiation Medium
以下の細胞の培養は全て、37℃5%CO2にて行った。
直径10cmの培養皿にMesenPro培地8mLを分注してBMSC細胞を維持培養した。細胞播種量は5×105cell/wellとし、培養期間は6日間とした。
脂肪への分化を確認した結果を図5、6に示す。(図5の脂肪細胞染色写真より、脂肪細胞に誘導された細胞数をカウントした結果が図6である)
細胞がBMSCであり、培地がMesenProである場合、脂肪分化誘導培地がLonza,PromoCellの何れの場合においても、CBE3添加によって脂肪分化が抑制されていた。CBE3添加量が2.8~280μg/mLである場合に顕著に脂肪分化抑制された。
(1)実験:CBE3添加(添加量:0、0.028、2.8、28μg/mL)
使用細胞:
ヒト骨髄由来細胞BMSC(Lonza:PT-2501)
使用培地:MesenPro(2%血清含有、ライフテクノロジーズ)
0.1質量%CBE3水溶液:cellnest(登録商標)(富士フイルム)
以下の細胞の培養は全て、37℃5%CO2にて行った。
直径10cmの培養皿にMesenPro培地8mLを分注して、passage5(第五継代細胞)まで維持培養した。細胞播種量は0.4~1.0×106cell/培養皿とし、培養期間は各継代毎に7日間前後とした。
細胞数を計測した結果を図7に示す。各々のCBE3濃度においてN=3で培養を行い、測定した結果の平均値を表す。CBE3無添加に比べ、CBE3の添加により7日間培養後の細胞数は増加した。細胞数の増加は2.8μg/mLのときがピークであり、更に高濃度とすることで細胞数は、減少傾向を示した。
Claims (16)
- コラーゲンの部分アミノ酸配列に由来するアミノ酸配列を有するリコンビナントゼラチンが溶解した液体培地において間葉系幹細胞を培養する工程を含む、脂肪細胞への分化が抑制された間葉系幹細胞の製造方法。
- リコンビナントゼラチンが、コラーゲンに特徴的なGly-X-Yで示される配列の繰り返しを有し、XおよびYはそれぞれ独立にアミノ酸の何れかを示し、複数個のGly-X-Yはそれぞれ同一でも異なっていてもよく、リコンビナントゼラチンの分子量が2kDa以上100kDa以下である、請求項1に記載の方法。
- リコンビナントゼラチンが、コラーゲンに特徴的なGly-X-Yで示される配列の繰り返しを有し、XおよびYはそれぞれ独立にアミノ酸の何れかを示し、複数個のGly-X-Yはそれぞれ同一でも異なっていてもよく、リコンビナントゼラチンの分子量が10kDa以上90kDa以下である、請求項1または2に記載の方法。
- リコンビナントゼラチンが、コラーゲンに特徴的なGly-X-Yで示される配列の繰り返しを有し、XおよびYはそれぞれ独立にアミノ酸の何れかを示し、複数個のGly-X-Yはそれぞれ同一でも異なっていてもよく、リコンビナントゼラチンが細胞接着シグナルを一分子中に2配列以上含む、請求項1から3の何れか一項に記載の方法。
- 細胞接着シグナルがArg-Gly-Aspで示されるアミノ酸配列である、請求項4に記載の方法。
- リコンビナントゼラチンのアミノ酸配列が、下記式で示される、請求項1から5の何れか一項に記載の方法。
A-[(Gly-X-Y)n]m-B式中、Aは任意のアミノ酸またはアミノ酸配列を示し、Bは任意のアミノ酸またはアミノ酸配列を示し、n個のXはそれぞれ独立にアミノ酸の何れかを示し、n個のYはそれぞれ独立にアミノ酸の何れかを示し、nは3~100の整数を示し、mは2~10の整数を示す。なお、n個のGly-X-Yはそれぞれ同一でも異なっていてもよい。 - リコンビナントゼラチンのアミノ酸配列が、下記式で示される、請求項1から6の何れか一項に記載の方法。
Gly-Ala-Pro-[(Gly-X-Y)63]3-Gly式中、63個のXはそれぞれ独立にアミノ酸の何れかを示し、63個のYはそれぞれ独立にアミノ酸の何れかを示す。なお、63個のGly-X-Yはそれぞれ同一でも異なっていてもよい。 - リコンビナントゼラチンが、(1)配列番号1に記載のアミノ酸配列、または(2)配列番号1に記載のアミノ酸配列と80%以上の配列同一性を有し、細胞接着性を有するアミノ酸配列を有する、請求項1から7の何れか一項に記載の方法。
- 間葉系幹細胞が、骨髄由来細胞または軟骨由来細胞である、請求項1から8の何れか一項に記載の方法。
- コラーゲンの部分アミノ酸配列に由来するアミノ酸配列を有するリコンビナントゼラチンが溶解した液体培地が、未分化維持用の液体培地である、請求項1から9の何れか一項に記載の方法。
- コラーゲンの部分アミノ酸配列に由来するアミノ酸配列を有するリコンビナントゼラチンが溶解した液体培地中の濃度が、0.01μg/mL~500μg/mLである、請求項1から10の何れか一項に記載の方法。
- コラーゲンの部分アミノ酸配列に由来するアミノ酸配列を有するリコンビナントゼラチンが溶解した液体培地中の濃度が、0.02μg/mL~300μg/mLである、請求項1から10の何れか一項に記載の方法。
- 請求項1から12の何れか一項に記載の方法により脂肪細胞への分化が抑制された間葉系幹細胞を製造する工程、および分化誘導培地において、前記の脂肪細胞への分化が抑制された間葉系幹細胞を培養する工程を含む、分化誘導された細胞の製造方法。
- 請求項1から12の何れか一項に記載の方法により製造される間葉系幹細胞。
- 請求項13に記載の方法により製造される分化誘導された細胞。
- コラーゲンの部分アミノ酸配列に由来するアミノ酸配列を有するリコンビナントゼラチンを含む、脂肪細胞への分化抑制剤。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18798627.8A EP3623466A4 (en) | 2017-05-12 | 2018-05-11 | PROCESS FOR THE PRODUCTION OF MESENCHYMATIC STEM CELLS AND RELATED APPLICATION |
CN201880031304.0A CN110869495B (zh) | 2017-05-12 | 2018-05-11 | 间充质干细胞的制造方法及其应用 |
JP2019517724A JPWO2018207923A1 (ja) | 2017-05-12 | 2018-05-11 | 間葉系幹細胞の製造方法、およびその応用 |
US16/678,873 US11649274B2 (en) | 2017-05-12 | 2019-11-08 | Method for producing mesenchymal stem cell and application of same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017095463 | 2017-05-12 | ||
JP2017-095463 | 2017-05-12 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/678,873 Continuation US11649274B2 (en) | 2017-05-12 | 2019-11-08 | Method for producing mesenchymal stem cell and application of same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018207923A1 true WO2018207923A1 (ja) | 2018-11-15 |
Family
ID=64105430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2018/018391 WO2018207923A1 (ja) | 2017-05-12 | 2018-05-11 | 間葉系幹細胞の製造方法、およびその応用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US11649274B2 (ja) |
EP (1) | EP3623466A4 (ja) |
JP (1) | JPWO2018207923A1 (ja) |
CN (1) | CN110869495B (ja) |
WO (1) | WO2018207923A1 (ja) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03228683A (ja) | 1989-12-20 | 1991-10-09 | Chemo Sero Therapeut Res Inst | 生理活性ペプチドLD78α、LD78βおよびその製法、これに用いる組換えプラスミド |
EP1014176A2 (en) | 1998-12-23 | 2000-06-28 | Fuji Photo Film B.V. | Silver halide emulsions containing recombinant gelatin-like proteins |
WO2004085473A2 (en) | 2003-03-28 | 2004-10-07 | Fuji Photo Film B.V. | Rgd-enriched gelatine-like proteins with enhanced cell binding |
US6992172B1 (en) | 1999-11-12 | 2006-01-31 | Fibrogen, Inc. | Recombinant gelatins |
JP2007326834A (ja) | 2006-06-09 | 2007-12-20 | Toray Ind Inc | ポリペプチド及び該ポリペプチドを固定化させた基材 |
WO2008103041A1 (en) | 2007-02-21 | 2008-08-28 | Fujifilm Manufacturing Europe B.V. | Recombinant gelatins |
JP2009136209A (ja) | 2007-12-06 | 2009-06-25 | Japan Health Science Foundation | 心筋細胞分化誘導促進剤及びその使用方法 |
WO2011108537A1 (ja) | 2010-03-02 | 2011-09-09 | 富士フイルム株式会社 | 細胞支持体及び骨再生材 |
JP2014198686A (ja) | 2013-03-29 | 2014-10-23 | オリエンタル酵母工業株式会社 | 脂肪分化を抑制する方法 |
JP2015043780A (ja) | 2007-06-29 | 2015-03-12 | 真理 船木 | 幹細胞の進展の調節における柔らかいゲル系 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100209382A1 (en) * | 2005-09-16 | 2010-08-19 | Ordway Research Institute, Inc. | Polyphenol Conjugates as RGD-Binding Compounds and Methods of Use |
WO2011006087A1 (en) * | 2009-07-10 | 2011-01-13 | The Regents Of The University Of California | Inhibition of ppar gamma expression in preadipocyte cells by oxysterols |
KR101744040B1 (ko) * | 2010-03-01 | 2017-06-07 | 후지필름 가부시키가이샤 | 생체 친화성을 갖는 고분자 블록과 세포로 이루어지는 세포 구조체 |
BR112014020119A2 (pt) * | 2012-02-13 | 2020-10-27 | Gamida-Cell Ltd | cultura de células-tronco mesenquimais |
JP2013234150A (ja) * | 2012-05-09 | 2013-11-21 | Kobe Gakuin | 脂肪細胞分化抑制剤 |
KR101535337B1 (ko) * | 2013-04-30 | 2015-07-09 | 고려대학교 산학협력단 | 지방세포 분화 과정에서 인간 작은 류신 지퍼 단백질의 용도 |
WO2016148245A1 (ja) | 2015-03-18 | 2016-09-22 | 富士フイルム株式会社 | 軟骨再生材料 |
-
2018
- 2018-05-11 WO PCT/JP2018/018391 patent/WO2018207923A1/ja active Application Filing
- 2018-05-11 CN CN201880031304.0A patent/CN110869495B/zh active Active
- 2018-05-11 EP EP18798627.8A patent/EP3623466A4/en active Pending
- 2018-05-11 JP JP2019517724A patent/JPWO2018207923A1/ja active Pending
-
2019
- 2019-11-08 US US16/678,873 patent/US11649274B2/en active Active
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03228683A (ja) | 1989-12-20 | 1991-10-09 | Chemo Sero Therapeut Res Inst | 生理活性ペプチドLD78α、LD78βおよびその製法、これに用いる組換えプラスミド |
EP1014176A2 (en) | 1998-12-23 | 2000-06-28 | Fuji Photo Film B.V. | Silver halide emulsions containing recombinant gelatin-like proteins |
EP1014176B1 (en) | 1998-12-23 | 2009-04-29 | FUJIFILM Manufacturing Europe B.V. | Silver halide emulsions containing recombinant gelatin-like proteins |
US6992172B1 (en) | 1999-11-12 | 2006-01-31 | Fibrogen, Inc. | Recombinant gelatins |
WO2004085473A2 (en) | 2003-03-28 | 2004-10-07 | Fuji Photo Film B.V. | Rgd-enriched gelatine-like proteins with enhanced cell binding |
JP2007326834A (ja) | 2006-06-09 | 2007-12-20 | Toray Ind Inc | ポリペプチド及び該ポリペプチドを固定化させた基材 |
WO2008103041A1 (en) | 2007-02-21 | 2008-08-28 | Fujifilm Manufacturing Europe B.V. | Recombinant gelatins |
JP2015043780A (ja) | 2007-06-29 | 2015-03-12 | 真理 船木 | 幹細胞の進展の調節における柔らかいゲル系 |
JP2009136209A (ja) | 2007-12-06 | 2009-06-25 | Japan Health Science Foundation | 心筋細胞分化誘導促進剤及びその使用方法 |
WO2011108537A1 (ja) | 2010-03-02 | 2011-09-09 | 富士フイルム株式会社 | 細胞支持体及び骨再生材 |
JP2014198686A (ja) | 2013-03-29 | 2014-10-23 | オリエンタル酵母工業株式会社 | 脂肪分化を抑制する方法 |
Non-Patent Citations (11)
Title |
---|
"Byotai Seiri (Pathophysiology", vol. 9, 1990, NAGAI SHOTEN CO., LTD., pages: 527 |
FRAGRANCE JOURNAL, vol. 50, 1981, pages 79 - 82 |
GASTEIGER E.GATTIKER A.HOOGLAND C.IVANYI I.APPEL R.D.BAIROCH A.: "ExPASy: the proteomics server for in-depth protein knowledge and analysis", NUCLEIC ACIDS RES., vol. 31, 2003, pages 3784 - 3788, XP055595893, DOI: 10.1093/nar/gkg563 |
GASTEIGER E.HOOGLAND C.GATTIKER A.DUVAUD S.WILKINS M.R.APPEL R.D.BAIROCH A.: "The Proteomics Protocols Handbook", 2005, HUMANA PRESS, article "Protein Identification and Analysis Tools on the ExPASy Server", pages: 571 - 607 |
KAGAKU NO RYOIKI (DOMAIN OF CHEMISTRY, vol. 11, no. 10, 1957, pages 719 - 725 |
KODA, YOSHIO ET AL.: "New Edition Organic Conceptual Diagram - Fundamentals and Applications", 2008, SANKYO SHUPPAN CO., LTD. |
LIN, YU-TING ET AL.: "Inhibition of adipogenesis by RGD-dependent disintegrin", BIOCHEM. PHARMACOL, vol. 70, no. 10, 15 November 2005 (2005-11-15), pages 1469 - 1478, XP055561199 * |
LIU, CHAO ET AL.: "Potential application of hydrolyzed fish collagen for inducing the multidirectional differentiation of rat bone marrow mesenchymal stem cells", BIOMACROMOLECULES, vol. 15, no. 1, 23 December 2013 (2013-12-23), pages 436 - 443, XP055561197 * |
NASU MTAKAYAMA SUMEZAWA A: "Endochondral ossification model system: designed cell fate of human epiphyseal chondrocytes during long-term implantation", J. CELL PHYSIOL., vol. 230, 2015, pages 1376 - 1388 |
PHARMACEUTICAL BULLETIN, vol. 2, no. 2, 1954, pages 163 - 173 |
See also references of EP3623466A4 |
Also Published As
Publication number | Publication date |
---|---|
CN110869495B (zh) | 2023-06-20 |
EP3623466A1 (en) | 2020-03-18 |
EP3623466A4 (en) | 2020-08-12 |
US20200140523A1 (en) | 2020-05-07 |
CN110869495A (zh) | 2020-03-06 |
US11649274B2 (en) | 2023-05-16 |
JPWO2018207923A1 (ja) | 2020-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sebinger et al. | ECM modulated early kidney development in embryonic organ culture | |
Mu et al. | A customized self-assembling peptide hydrogel-wrapped stem cell factor targeting pulp regeneration rich in vascular-like structures | |
WO2017221879A1 (ja) | トロフィックファクタ放出剤および炎症疾患処置剤 | |
JP2016188235A (ja) | 細胞と生体適合性高分子を含む組成物 | |
Wang et al. | Designer self-assembling peptide nanofiber scaffolds containing link protein N-terminal peptide induce chondrogenesis of rabbit bone marrow stem cells | |
WO2016027850A1 (ja) | 間葉系幹細胞用培地 | |
Langenbach et al. | Osteogenic differentiation influences stem cell migration out of scaffold-free microspheres | |
EP3460050B1 (en) | Cell culturing method, culture medium, and culture medium kit | |
WO2021025027A1 (ja) | 皮膚由来多能性前駆細胞の作製方法 | |
WO2018207923A1 (ja) | 間葉系幹細胞の製造方法、およびその応用 | |
Peinkofer et al. | Persistence of intramyocardially transplanted murine induced pluripotent stem cell-derived cardiomyocytes from different developmental stages | |
JP7360672B2 (ja) | 間葉系幹細胞からインスリン産生細胞を製造する方法、インスリン産生細胞、細胞構造体および医薬組成物 | |
US20200015475A1 (en) | Cell mass or cell structure-embedding agent, cell mass or cell structure-containing composition, and kit | |
EP3848063A1 (en) | Gel formation kit, gel, and gel production method | |
Chen et al. | Odontogenic MSC heterogeneity: challenges and opportunities for regenerative medicine | |
JP2008061569A (ja) | 幹細胞の培養方法及びその培地 | |
KR20180129726A (ko) | 세포와 세포간의 결합 증진을 위한 고분자 지지체 및 이를 이용한 세포 배양 방법 | |
JP5882198B2 (ja) | ラミニン5を含んだ系で細胞を培養する方法 | |
EP4005597A1 (en) | Biograft material | |
van Osch et al. | Cells for Cartilage Regeneration | |
Sachenberg et al. | Spreading and actin cytoskeleton organization of cartilage and bone marrow stromal cells cocultured on various extracellular matrix proteins | |
JP5904358B2 (ja) | 平行線維性結合組織の製造方法 | |
Belair | POSTER CONTEST FINALISTS | |
Montella et al. | Dental pulp stem cells: State of the art and suggestions for a true translation of research into therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18798627 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2019517724 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2018798627 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2018798627 Country of ref document: EP Effective date: 20191212 |